The treatment with the chemotherapeutic agent paclitaxel produces a painful peripheral neuropathy, and is associated with an acute pain syndrome in a clinically significant number of patients. However, no standard therapy has been established to manage the acute pain or the chronic neuropathic pain related to paclitaxel. In the present study, we evaluated the analgesic potential of two N-type voltage-gated calcium channel (VGCC) blockers, ω-conotoxin MVIIA and Phα1β, on acute and chronic pain induced by paclitaxel. Adult male rats were treated with four intraperitoneal injections of paclitaxel (1 + 1 + 1 + 1 mg/kg, in alternate days) and the development of mechanical hyperalgesia was evaluated 24 h (acute painful stage) or 15 days (chronic painful stage) after the first paclitaxel injection. Not all animals showed mechanical hyperalgesia 24 h after the first paclitaxel injection, but those that showed developed a more intense mechanical hyperalgesia at the chronic painful stage. Intrathecal administration (i.t.) of ω-conotoxin MVIIA (3-300 pmol/site) or Phα1β (10-300 pmol/site) reduced the mechanical hyperalgesia either at the acute or at the chronic painful stage induced by paclitaxel. When administered at the acute painful stage, ω-conotoxin MVIIA (300 pmol/site, i.t.) and Phα1β (300 pmol/site, i.t.) prevented the worsening of chronic mechanical hyperalgesia. Furthermore, Phα1β (30-300 pmol/site, i.t.) elicited less adverse effects than ω-conotoxin MVIIA (10-300 pmol/site, i.t.). Taken together, our data evidence the involvement of N-type VGCC in pain sensitization induced by paclitaxel and point out the potential of Phα1β as a safer alternative than ω-conotoxin MVIIA to treat the pain related to paclitaxel.
Introduction
Paclitaxel is a chemotherapeutic agent commonly used in solid tumors (Rowinsky et al., 1993; . The main side effect associated with long-term use of paclitaxel is a chronic peripheral neuropathy, characterized by mechanical hyperalgesia, tingling and numbness affecting the distal extremities (Rowinsky et al., 1993; Forsyth et al., 1997; Dougherty et al., 2004; Woolf et al., 2008) . The onset of sensory symptoms during paclitaxel treatment usually leads to a reduction in the dose or interruption of therapy, which can negatively affect cancer therapy outcomes Dougherty et al., 2004) . Moreover, it has been recently reported that paclitaxel is also associated with an acute pain syndrome that develops in the first days of treatment, and affects a large proportion of patients (Loprinzi et al., 2007 (Loprinzi et al., , 2011 Reeves et al., 2012) . Furthermore, the acute pain experienced by some patients in the beginning of the treatment with paclitaxel appears to be somehow related to the severity of the later neuropathic pain (Loprinzi et al., 2011; Reeves et al., 2012) . The chronic neuropathic pain induced by paclitaxel has been studied using animal models Naguib et al., 2012) , however, to our knowledge, no preclinical studies have addressed the acute pain induced by paclitaxel or its influence in chronic neuropathic pain.
Currently, there are no standard therapies to prevent or minimize the pain related to paclitaxel (Rowinsky et al., 1993; Gordon et al., 1997; Wasserheit et al., 1996; Loprinzi et al., 2011; Reeves et al., 2012) . Nevertheless, several lines of evidence suggest the involvement of voltage-gated calcium channels (VGCC) in pain arising from nerve damage (Piekarz et al., 2012; Arcos et al., 2013; Kukkar et al., 2013) , including those induced by chemotherapeutic agents (Flatters and Bennett, 2004; Siau et al., 2006; Xiao et al., 2007; Saif and Hashmi, 2008; Kawakami et al., 2012) . Furthermore, a N-type VGCC blocker peptide derived from the venom of the cone snail Conus magus, the ω-conotoxin MVIIA, had its synthetic form, ziconotide, recently approved for the treatment of severe chronic pain, including neuropathic pain refractory to other therapies (Staats et al., 2004; Prommer, 2006) . However, whether ziconotide alleviates the pain related to paclitaxel treatment is yet to be investigated.
The clinical use of ziconotide, despite having confirmed the good analgesic efficacy of ω-conotoxin MVIIA, has revealed to cause serious adverse effects (Penn and Paice, 2000; Rauck et al., 2009; Achim et al., 2010; Maier et al., 2011) . We have been studied the analgesic potential of a peptide toxin isolated from the venom of the Brazilian spider Phoneutria nigriventer, named Phα1β, which inhibits VGCC, mainly the N-type calcium currents (Vieira et al., 2005) in several animal models of pain (Souza et al., 2008; de Souza et al., 2011 de Souza et al., , 2013 Castro-Junior et al., 2013; Rigo et al., 2013) . The Phα1β has shown antinociceptive effect with a larger therapeutic window when comparing to ω-conotoxin MVIIA (Souza et al., 2008; Castro-Junior et al., 2013; Rigo et al., 2013) .
The primary goal of the present study was evaluate the analgesic potential of ω-conotoxin MVIIA and Phα1β in the acute and chronic neuropathic pain induced by paclitaxel. We showed that both VGCCs reduced the acute and chronic mechanical hyperalgesia induced by paclitaxel, but Phα1β produced less adverse effects than ω-conotoxin MVIIA. In addition, we described a positive relation between the development of acute pain and the degree of chronic neuropathic pain induced by paclitaxel that can be controlled by spinal injection of both VGCC blockers.
Materials and methods

Animals
Male adult Wistar rats weighing 250-300 g were used. All experimental procedures were approved by the ethics committee of the Federal University of Santa Maria (process number: 23081.005024/2010-88), and were carried out in accordance with the guidelines for the care of laboratory animals and the ethical guidelines for investigations of experimental pain in conscious animals (Zimmermann, 1983) .
Drugs
Phα1β was purified from the venom of the Brazilian spider P. nigriventer, as previously described (Cordeiro et al., 1993) . The N-type VGCC blocker ω-conotoxin MVIIA was purchased from Latoxan (Valence, France). Phα1β and ω-conotoxin MVIIA were dissolved in phosphatebuffer saline (PBS; pH 7.4). Paclitaxel (6 mg/mL paclitaxel in Cremophor EL and dehydrated ethanol) was purchased from Glenmark (Buenos Aires, Argentina), and was dissolved in saline solution (NaCl, 0.9%).
Paclitaxel-induced acute and chronic pain model
Different group of rats received one or four intraperitoneal (i.p.) injections of paclitaxel (1 mg/kg), injected on alternate days . Acute pain was evaluated from 24 to 72 h after a single injection of paclitaxel. Chronic pain was evaluated at 7, 15, 22, and 30 days after the first of four paclitaxel injections. Acute pain and chronic pain were evaluated using the von Frey test, which measures mechanical sensitivity. Mechanical hyperalgesia was defined as a reduction of the baseline paw withdrawal threshold of ≥50% after paclitaxel treatment.
Behavioral tests
Von Frey test
Mechanical threshold was measured by applying von Frey filaments on the plantar surface (sciatic nerve territory) of the rat's hindpaw, using the up-down method, as described previously (Chaplan et al., 1994; Dixon, 1980) . Briefly, rats were first acclimatized (1-2 h) in individual clear Plexiglas boxes on an elevated wire mesh platform to allow access to the plantar surface of the hind paws. Von Frey filaments of increasing stiffness (6-100 g) were applied to the hind paw plantar surface of the animals with a pressure high enough to bend the filament. The absence of a paw lifting after 5 s led to the use of the next filament with increasing weight, whereas paw lifting indicated a positive response and led to the use of the next weaker filament. This paradigm continued for a total of 6 measurements, including the one before the first paw-lifting response had been made, or until 4 consecutive positive or 4 consecutive negative responses occurred. The 50% mechanical paw withdraw threshold (PWT) response was then calculated from the resulting scores as described previously by Dixon. The PWT was expressed in grams (g).
Adverse effects assessment
Adverse effects elicited by the treatments, such as serpentine-like tail movement, body shaking and allodynia were assessed and quantified using a 7-point scale, as previously described (Smith et al., 2002; Malmberg and Yaksh, 1994) .
Experimental design
The ω-conotoxin MVIIA and Phα1βwere administered by intrathecal (i.t.) route, as previously described (Dalmolin et al., 2011) .
First, we evaluated the time-course of paclitaxel-induced acute and chronic pain in two separated group of rats. In one group of rats, the mechanical hyperalgesia was evaluated from 24 to 72 h after a single injection of paclitaxel (1 mg/kg, i.p.). In another group, rats received 4 injections of paclitaxel (1 + 1 + 1 + 1 mg/kg, i.p., in alternate days) and after 7, 15, 22, and 30 days of the first paclitaxel injection they had their mechanical threshold examined.
Next, the time-course and the dose-response curve of antinociceptive and adverse effects caused by i.t. treatment with ω-conotoxin MVIIA (3-300 pmol/site) and by Phα1β (10-300 pmol/site) were evaluated on acute pain (24 h after a single injection of paclitaxel) and chronic neuropathic pain (15 days after the first injection, in rats receiving 4 paclitaxel injections) induced by paclitaxel, in separated group of rats. The next step was to investigate whether N-type VGCC blockade in the acute painful stage affects the mechanical hyperalgesia in the chronic painful stage. In brief, rats had their mechanical sensitivity evaluated before and 24 h after the first of four paclitaxel injections (1 mg/kg, i.p.). Those rats that showed mechanical hyperalgesia (reduction of the baseline PWT ≥ 50%), were considered as part of the group that developed acute pain, called acute pain affected group. The rats that did not show mechanical hyperalgesia were classified as acute pain non-affected group. Once the mechanical hyperalgesia was established, the acute pain affected group was treated with PBS (10 μl/site, i.t.), Phα1β (300 pmol/site, i.t.), or ω-conotoxin MVIIA (300 pmol/site, i.t.) and evaluated from 15 to 360 min post-treatment in the von Frey test. Then, both acute pain affected and non-affected groups continued receiving the next three paclitaxel injections in alternate days, and had their mechanical sensibility re-evaluated 15 days after the first injection, at the chronic painful stage. At this stage, those rats showing mechanical hyperalgesia were treated with PBS (10 μl/site, i.t.), Phα1β (300 pmol/site, i.t.), or ω-conotoxin MVIIA (30 pmol/site, i.t.), and had their mechanical threshold evaluated from 15 to 360 min. A schematic representation of the experimental design can be found in Fig. 1 .
In all experiments, the rats were randomly assigned to individual experimental groups and the subsequent behavioral tests were performed by an experimenter blind to the treatment conditions. Each experiment was performed at least two times.
Statistical analysis
Statistical analysis was performed using GraphPad Prism Version 5.01. Data were analyzed using a Student's t-test, and one-way or two-way analysis of variance (ANOVA), followed by Bonferroni or StudentNewman-Keuls (SNK) tests when appropriate. Adverse effects were analyzed by Kruskal-Wallis followed by Dunn's test, when appropriate. For analysis of proportions, the χ 2 test was used. The effective dose 50%
(ED 50 ) and the toxic dose 50% (TD 50 ) values were calculated by nonlinear regression using a dose-response equation adjusted to provide the best description of the values of the individual experiments. Values of P b 0.05 were considered significant. The results are presented as mean ± standard error (PWT), as median ± interquartile range (adverse effect scores), or as geometric means accompanied by their respective 95% confidence limits (ED 50 and TD 50 ).
Results
Antinociceptive effect of ω-conotoxin MVIIA and Phα1β on acute and chronic pain induced by paclitaxel
The effect of i.t. administration of ω-conotoxin MVIIA and Phα1β on the mechanical hyperalgesia induced by a single injection or by 4 injections of paclitaxel (1 mg/kg, i.p) was evaluated in rats. A single injection of paclitaxel (1 mg/kg, i.p.) induced acute mechanical hyperalgesia (reduction of PWT from 67.1 ± 10.6 g to 15.4 ± 4.0 g; P b 0.01, 2-way ANOVA) at 24 h, that was no longer detected at 48 h ( Fig. 2A) . The PWT of rats injected with saline (control group) remained unchanged (64.5 ± 11.5 g at baseline and 51.7 ± 12.2 g 24 h post-saline injection). Four injections of paclitaxel produced a further reduction in the mechanical threshold of rats, observed from 7 to 30 days after the beginning of the treatment, reaching the maximum effect at day 15 (reduction of PWT from 50.2 ± 7.6 g to 9.9 ± 1.1 g; P b 0.001, 2-way ANOVAFig. 2B). No difference was found in control group (Fig. 2B) . Therefore, the effects of ω-conotoxin MVIIA and Phα1β on paclitaxelinduced acute and chronic pain were evaluated after 24 h (acute painful stage) or 15 days of the first paclitaxel injection (chronic painful stage). When tested at acute painful stage, administration of ω-conotoxin MVIIA (30-300pmol/site, i.t.) inhibited 89±20% (I max ) of the mechanical hyperalgesia induced by a single injection of paclitaxel (1 mg/kg, i.p.), with an estimated ED 50 value (95% confidence limits) of 94 (52-170) pmol/site (Fig. 3A) . Statistically significant antinociceptive effect was found from 15 to 240 min post-administration (Fig. 3B) . When administered at chronic painful stage, the ω-conotoxin MVIIA exhibited the same effectiveness and time-course observed in the acute stage, inhibiting up to 100% (I max ) of the mechanical hyperalgesia from 15 to 240 min (Fig. 3D ), but showed greater potency, with ED 50 value (95% confidence limits) of 5 (2-12) pmol/site (Fig. 3C) . Likewise, Phα1β (10-300 pmol/site) inhibited both acute (I max = 100%) and chronic (I max = 81 ± 10%) mechanical hyperalgesia from 15 to 240 postadministration ( Fig. 3E-H The ω-conotoxin MVIIA (10-100 pmol/site) induced significant adverse effects, such as serpentine tail movements, body shaking, and dynamic allodynia. All doses of ω-conotoxin MVIIA elicited adverse effects in acute and chronic painful stage, but a higher frequency was observed when injected at chronic stage (Table 1 ). The estimated TD 50 value (95% confidence limits) and therapeutic index (TD 50 /ED 50 ) of ω-conotoxin MVIIA were 26 (16-43) pmol/site and 0.3, in the acute painful stage, and 22 (15-33) pmol/site and 4.4 in the chronic painful stage. On the other hand, Phα1β (30-300 pmol/site) produced minor adverse effects when injected at acute or chronic painful stage (Table 1) . Dynamic allodynia was observed only after the highest dose tested (300 pmol/site), hindering the estimation of the TD 50. 
Effect of blocking N-type VGCC at the acute painful stage on the chronic mechanical hyperalgesia induced by paclitaxel
In our experimental conditions, of all rats treated with paclitaxel, 32 ± 8% did not show mechanical hyperalgesia neither at acute nor at chronic painful stage. From those rats that showed mechanical hyperalgesia (67 ± 8%), all of them showed it at chronic stage. Of rats showing chronic mechanical hyperalgesia, 44 ± 5% also showed mechanical hyperalgesia at acute stage. Notably, all animals affected by acute pain also showed mechanical hyperalgesia at chronic stage. Moreover, rats from the acute pain affected group (mean PWT of 67.1 ± 10.6 g at baseline and 21.8 ± 6.3 24 h after paclitaxel) showed greater hyperalgesia at chronic painful stage than acute pain nonaffected rats (mean PWT of 8.1 ± 0.5 g for acute pain affected group and 18.5 ± 4.7 for acute pain non-affected group after 15 days of the first paclitaxel injection - Fig. 4A ).
We therefore investigated whether the administration of ω-conotoxin MVIIA and Phα1β at acute painful stage (24 h after the first paclitaxel injection) affect the mechanical hyperalgesia at the chronic painful stage (15 days after the first paclitaxel injection). Intrathecal treatment of acute pain affected rats with ω-conotoxin MVIIA (300 pmol/site) and Phα1β (300 pmol/site) at acute stage prevented the further intensification of mechanical hyperalgesia at chronic stage (mean PWT of 8.3 ± 1.2, 21.4 ± 5.0, and 21.8 ± 3.3 g for PBS-treated group, ω-conotoxin MVIIA-treated group and for Phα1β-treated group, respectively; P b 0.05, 1-way ANOVA - Fig. 4B ).
Discussion
Most of patients complain of pain at the early or later stage of paclitaxel treatment Loprinzi et al., 2007; Reeves et al., 2012) . However, no standard therapy has been established to manage the acute or the chronic neuropathic pain related to paclitaxel. In the present study, we evaluated the analgesic potential of two N-type c blockers, ω-conotoxin MVIIA and Phα1β, on an experimental model of paclitaxel-induced acute and chronic pain. We showed that ω-conotoxin MVIIA and Phα1β reduced the acute and the chronic mechanical hyperalgesia induced by paclitaxel, but Phα1β showed superior therapeutic index than ω-conotoxin MVIIA. We also showed a positive relation between the development of the acute pain and the worsening of chronic pain induced by paclitaxel that can be prevented by both VGCC blockers.
The paclitaxel-associated acute pain syndrome is a severe and debilitating condition, described in up to 58% of patients (Loprinzi et al., 2007 (Loprinzi et al., , 2011 . Although frequent, most pre-clinical studies have focused on chronic neuropathic pain induced by paclitaxel, overlooking the acute pain. Interesting, by applying a 4-day injection protocol of paclitaxel treatment, known to cause a chronic painful neuropathy , we observed the development of mechanical hyperalgesia after the first injection of paclitaxel in 44% of the rats treated. A single injection of paclitaxel induced mechanical hyperalgesia after 24 h, which was no longer detected at 48 h. Likewise, in humans the acute pain symptoms usually begin within 1 to 2 days of paclitaxel administration (Loprinzi et al., 2007) , demonstrating that this is a suitable model to study the acute pain induced by paclitaxel.
Recent evidences have shown that patients under paclitaxel treatment who experience intense pain following the first cycle of administration develop a more severe peripheral neuropathy in a later stage (Loprinzi et al., 2011; Reeves et al., 2012) , suggesting that the acute pain induced by paclitaxel is related to the degree of pain associated to a posterior nerve injury. In addition, other studies have shown that although the neurotoxicity produced by paclitaxel is cumulative, the onset of sensory symptoms may begin within 24-72 h following the first administration (Holmes et al., 1991; Rowinsky et al., 1993) . In our study, while some rats did not developed acute mechanical hyperalgesia after the first paclitaxel administration (56%), all rats that developed it also showed mechanical hyperalgesia at chronic stage. Interesting, those rats that developed acute pain showed a more intense mechanical hyperalgesia at chronic stage. Thus, it seems that the acute pain is related to the severity of the chronic pain symptoms. Therefore, the prophylactic treatment at acute pain stage might prevent the worsening of chronic painful symptoms. In agreement, we showed that administration of ω-conotoxin MVIIA or Phα1β not only reduced the acute mechanical hyperalgesia induced by paclitaxel but also prevented the worsening of the associated chronic pain.
The paclitaxel-induced acute pain has been attributed to the sensitization of nociceptors (Loprinzi et al., 2007) . However, the molecular mechanisms involved in such sensitization are still unclear. The N-type VGCC are highly expressed on nociceptor terminals in laminae I and II of the dorsal horn of the spinal cord, where they mediate calcium-induced synaptic vesicle release (Perret and Luo, 2009; Zamponi et al., 2009) . Through spinal glutamate release, N-type VGCCs play an important role in regulating neuronal excitability and nociceptive transmission, being prominently involved in the transduction of acute pain signals (Snutch, 2005) . Both the ω-conotoxin MVIIA and the Phα1β have shown to inhibit calcium influx and glutamate release from spinal cord of rats following acute pain stimulus (Souza et al., 2008) . In this study, we showed that the spinal injection of both VGCC blockers reduced the acute mechanical hyperalgesia induced by paclitaxel, supporting the involvement of N-type VGCC in nociceptor sensitization following paclitaxel injection. In accordance, there are reports that the anticonvulsant gabapentin, which inhibits VGCC activity by binding to the auxiliary subunit α2δ, may be helpful for alleviating paclitaxelassociated acute pain in patients (Garrison et al., 2003) . Several studies have highlighted the involvement of VGCC in the chronic neuropathic pain induced by paclitaxel. The N-type VGCC blocker, NMED-126, reduces the chronic neuropathic pain induced by paclitaxel in rats (Xiao et al., 2007) . Using the patch clamp technique, Kawakami et al. (2012) , demonstrated that paclitaxel treatment (4 mg/kg, i.p., injected in rats in 4 alternate days) increases VGCC current in small-and mediumdiameter DRG neurons after 7 days of the first injection. Furthermore, both the increase in VGCC currents and the mechanical hyperlagesia induced by paclitaxel were inhibited by gabapentin (Kawakami et al., 2012) . Similarly, here we showed that the VGCC blockers ω-conotoxin MVIIA and Phα1β reduced the mechanical hyperalgesia of rats undergoing chronic neuropathic pain induced by paclitaxel. Interestingly, the ω-conotoxin MVIIA reduced both the acute and the chronic pain induced by paclitaxel with a similar efficacy, but it showed a higher potency in the chronic neuropathic painful stage. It has been shown that in neuropathic states the high frequency of fiber activation produces a dynamic change in the VGCC conformational state, which switch between resting, activated, and inactivated (Winquist et al., 2005) . Depending on the VGCC conformational state, the affinity of some VGCC blockers are improved, as occurs with some ω-conotoxins, which exhibit higher potency when binding to the inactivated state of N-type VGCC (Stocker et al., 1997) . Although ω-conotoxin MVIIA can block N-type VGCC irrespective of the conformational state of the channel, the N-type VGCC can assume two conformations upon ω-conotoxin MVIIA binding, which differ in their stability (Feng et al., 2003) . For this reason, we believe that in the chronic neuropathic stage induced by paclitaxel the N-type VGCC is in a conformational state that favors the stability of ω-conotoxin MVIIA binding, increasing the ω-conotoxin MVIIA affinity and therefore its potency.
The ω-conotoxin MVIIA has received particular notoriety because its synthetic version ziconotide (Prialt®) is currently used to treat severe refractory pain (Staats et al., 2004) . However, serious adverse effects have been reported following ziconotide administration (Staats et al., 2004; Ayuga-Loro et al., 2011) . Here, we showed for the first time that ω-conotoxin MVIIA is efficacious against experimental paclitaxel pain model. On the other hand, the rats injected with ω-conotoxin MVIIA showed severe motor and sensorial adverse effects. Unlike ω-conotoxin MVIIA, the Phα1β elicited minimal adverse effects at the highest dose tested. Although both Phα1β and ω-conotoxin MVIIA inhibit N-type calcium currents (Kristipati et al., 1994; Vieira et al., 2005; Wang et al., 1998) , it is possible that they do not share identical docking sites on the N-type VGCC, as described for the ω-conotoxins MVIIA and GVIA (Feng et al., 2003) . A probable difference in the binding sites of both VGCC blockers would explain the difference in potency of ω-conotoxin MVIIA, but not of Phα1β, in chronic painful stage as well.
Concluding remarks
In the present study we showed evidences that both acute and chronic pain induced by paclitaxel can be reduced by Phα1β and ω-conotoxin MVIIA, and that the administration of both N-type VGCC blockers at the acute painful stage can prevent the worsening of pain in the chronic neuropathic stage. Furthermore, Phα1β exhibited superior therapeutic profile than ω-conotoxin MVIIA. Taken together, our data support the involvement of N-type VGCCs in pain sensitization induced by paclitaxel and point out the potential of Phα1β as a safer alternative than ω-conotoxin MVIIA to treat the pain related to paclitaxel. Fig. 4 . Relation between the presence of acute mechanical hyperlagesia and the degree of chronic mechanical hyperalgesia induced by paclitaxel. Comparison of chronic mechanical hyperalgesia between acute pain-affected group and acute pain non-affected group (A). Effect of ω-conotoxin MVIIA (300 pmol/site, i.t.) and Phα1β (300 pmol/site) on acute and chronic pain induced by paclitaxel (PAC-1+1+1+1 mg/kg, i.p., in alternate days) in acute-pain affected rats (B). Acute and chronic mechanical hyperalgesia were evaluated 24 h or 15 days after the first paclitaxel injection. The data displayed in A correspond to PBS-treated rats. The effects are expressed as PWT (g). B in the x axis denote the baseline PWT before paclitaxel treatment. Each column represents the mean of 5-8 rats, and vertical lines show the SEM. Statistical analysis was performed using a 1-way analysis of variance (ANOVA) followed by Student-Newman-Keuls posttest; ⁎Pb0.05, ⁎⁎Pb0.01, ⁎⁎⁎Pb0.001 denote the level of significance in comparison to baseline PWT before paclitaxel treatment; 
